Contrast-induced nephropathy (CIN) also called contrast-induced acute kidney injury (CI-AKI) has been on the agenda since the 1970s. In the early 1970s (before computed tomography [CT], magnetic resonance imaging [MRI], and ultrasound were used for diagnostic purposes) researchers found that so-called high-dose urography, often performed with conventional tomography of the kidneys, could visualize the outline of the kidney: (i) whether it was small, enlarged, or normalsized; (ii) whether the outline of the kidney was smooth or not; and (iii) whether there was dilatation of the pelvic cavity (hydronephrosis) or not. A lot of highosmolar contrast medium was required and at the same time, the amount of radiation was high. It was
even performed in patients with a transplanted kidney (1) . The images were considered beautiful and a major diagnostic step. High-dose urography opened a new era for radiology (2) . It took some time before the radiologists became aware of the fact that high doses of highosmolar contrast media might harm the kidney function.
The first case of CIN was published in 1954 (3) . It was a case of acute anuria in a patient with myelomatosis. The radiologists started to restrict the use of contrast media in patients with multiple myeloma and initially overlooked that hydration and decreased renal function were important factors. However, if dehydration is avoided, contrast-medium administration rarely leads to acute renal failure in patients with myeloma (4) . Until we got the non-ionic agents, it was a routine to ask the patient to stop intake of fluid for at least 6 h before an intravenous urography in order to avoid dilution of the contrast in the pelvis and the ureter.
In the late 1970s, radiologists stopped using increased doses of the contrast media in patients with reduced renal function. Some even stopped administrating contrast media to these patients. This may be one of several reasons why it took so many years before it was documented that the prevalence of CIN is higher after ionic high-osmolar contrast media than non-ionic agents (5) , since the ''high-risk'' patients were denied contrast medium. Another explanation is the low number of participants in the various studies at that time; a meta-analysis was necessary to document that there is a difference in nephrotoxic potential between ionic high-osmolar and non-ionic low-osmolar agents. It was not until 2003 that the general interest in CIN really took off. Aspelin et al. (6) showed in a randomized trial involving only 129 patients with moderate chronic kidney disease and diabetes mellitus, a significantly higher incidence of CIN (defined as an absolute increase in serum creatinine greater than 44 mmol/L) within 72 h with intra-arterial iohexol than with iodixanol (26% vs. 4%). The two groups differed significantly with regard to interventional procedures and duration of diabetes, but were otherwise comparable. This publication started a commercial fight between the various pharmaceutical companies whether the dimer was really less nephrotoxic than the monomers. Sessions dealing with CIN attracted a lot of participants at congresses. In 2009, Laskey et al. (7) had repeated Aspelin et al.'s study (6) in a larger group of similar patients; no difference between the monomer (Iopamidol) and the dimer (Iodixanol) was found. It taught us that one should never rely on a single study, at least when it is about adverse reactions to contrast media. The large majority of studies dealing with CIN was and is still performed in relation to cardiac angiography; only a small number of studies were done in patients receiving the contrast medium intravenously. CT patients are most frequently outpatients; thus it is difficult to check the patient -including taking a blood sample 72 h after the scanning. Based on a meta-analysis from the same year, Heinrich et al. (8) concluded that the iso-osmolar non-ionic iodixanol is not associated with a reduced risk of CIN compared to non-ionic monomers after intravenous administration. In patients with renal injury given contrast media intraarterially, low-osmolar iohexol was associated with a greater risk of CIN than iodixanol, but no significant difference between iodixanol and other non-ionic agents was found. We have no pathophysiological explanation for why iohexol should be more nephrotoxic than the other agents. It was used as comparator in many studies. The attention to CIN sessions decreased to the levels before 2003.
In 2006, Rao and Newhouse (9) did a critical literature analysis regarding CIN and found only two papers where a control group (receiving no contrast) was included. The two papers showed no significant difference between the two groups regarding CIN. In 2008, Newhouse et al. (10) identified, by examining the database of all patients seen at a large hospital, similar incidence of acute nephropathy not significantly different from the incidences reported for CIN after administration of contrast medium. Thus, one can find similar changes in S-creatinine levels (or eGFR) in patients who had contrast medium and who had no contrast medium. Accordingly, Azzouz et al. (11) found in 716 outpatients undergoing MRI or CT with or without contrast medium and who had their eGFR determined just before CT or MRI and 72 h later, that eGFR varied independently of whether the patient had received contrast or not. There was no difference between the four groups. The three patients who had CIN according to the absolute definition (>44 mmol/L) had had no contrast medium.
In a retrospective study, McDonald et al. (12) identified all enhanced and unenhanced abdominal, pelvic, and thoracic CT scans from 2000 through 2010 at a single facility and correlated them with S-creatinine determinations. The post-scan determination (one or more) of S-creatinine should have taken place 24-72 h after imaging and there should be at least one determination in the 24-h window before scanning. The absolute definition of CIN (>44 mmol/L) was used. The incidence of acute kidney injury was compared between enhanced and non-enhanced groups after propensity score adjustment. A total of 157,140 scans among 53,439 unique patients associated with 1,510,001 S-creatinine values were identified. Following adjustment for presumed risk factors, the incidence of CIN was not significantly different from ''CIN'' in the group that had no contrast medium. Acute kidney injury (CIN) was not significantly different between the two groups in any risk subgroup after propensity score adjustment. Also Davenport et al. (13) used propensity matching. They identified 20,242 unenhanced and enhanced CT examinations performed over a 10-year period in adult inpatients with sufficient S-creatinine data. Patients with creatinine levels less than 132.6 mmol/L before CT were not at risk of CIN, and the risk increased with increasing S-creatinine levels. Despite a number of risk factors other than contrast medium helped to predict renal dysfunction after administration of contrast medium, contrast medium administration remained an independent risk factor for patients with S-creatinine levels above 141 mmol/L. In another study done by McDonald et al. (14) , a total of 12,508 propensity score-matched patients with enhanced or unenhanced scans met the inclusion criteria: (i) CT-scanned from 2000 through 2010; (ii) S-creatinine determined 24 h before and 24-72 h after CT; (iii) had necessary demographic variables for the Modification of Diet in Renal Disease (MDRD)) equation. Excluded were patients on dialysis and who had additional contrast procedures within 14 days. The patients were divided according to their eGFR (>90, 60-89, 30-59, and <30 mL/min 1.73 m 2 ). Propensity score generation and 1:1 matching of patients were performed in each eGFR subgroup. Incidence of ''CIN'' defined as S-creatinine increase of 44 mmol/L was compared in the matched subgroups. They could not document that administration of contrast medium increased the risk of acute kidney injury even in patients with substantially compromised renal function. However, it is untold how many patients had eGFR below 20 mL/min 1.73m 2 and, if any, on which grounds they were included, e.g. emergency CT.
McDonald et al. (15) did a systematic review in 2013 and a meta-analysis of controlled studies examining the incidence of acute kidney injury in patients CT-scanned with or without iodine-based contrast medium. They identified 1489 studies, but only 13 (0.9%) fulfilled the inclusion criteria (incidence of acute kidney injury in patients exposed to intravenous contrast medium was directly compared with the incidence of acute kidney injury in unexposed patients through analyses of changes in S-creatinine level or estimated GFR 48-72 h following procedures or administration). Two of the 13 studies where those identified by Roa and Newhouse in 2006 (9) , and only four were prospective. The authors came to the conclusion that controlled CIN studies demonstrate a similar incidence of acute kidney injury, dialysis, and death between the contrastmedium group and control groups. It was observed regardless of intravenous contrast-medium type, diagnostic criteria for acute kidney injury or whether the patients had diabetes mellitus or renal injury. The study questions the existence of CIN.
Retrospective studies in this field are not optimal. First, why was the contrast medium not administered? Was it because the patient had poor renal function or simply because the CT scan was done to visualize renal calculi for which purpose unenhanced CT scans are sufficient in most cases. Second, why was the S-creatinine level determined 24-72 hours after imaging? Was the patient in special circumstances that necessitated this determination? Blood samples are not taken for fun.
Third, were preventive measures used in the group undergoing enhanced CT? It is possible, but very unlikely in the control group. Fourth, most of the patients undergoing CT are outpatients, but the majority in the retrospective studies are inpatients. In general, inpatients are sicker than outpatients.
The lessening of diagnostic information caused by withholding contrast medium and the diminished effectiveness of therapeutic management are probably considerable (16) . Of additional cost are the protocols requiring patient questionnaires, informed consent procedures, and renal function tests. Reduced renal function after contrast-medium exposure is often believed to be due to the contrast medium although there is no evidence for it; only that the patient had contrast medium intravenously in relation to a CT scan (16) .
Have we for 40 years been looking for and tried to prevent something that might be normal fluctuations of a poor parameter of renal function (10, 11) , at least in patients with moderately reduced renal function? Neither S-creatinine nor estimated GFR are perfect expressions of renal function (17) . S-creatinine levels are very variable. State of hydration, active secretion (increases with decreasing renal function), food intake (e.g. beef), muscular mass, drugs, physical activity, etc. are just some of the factors that influence the levels of S-creatinine. Nevertheless, we have used it for many years, but it is by no means optimal (17), but we do not have yet another easy and cheap method. The answer to the question is ''to some extent, yes''.
There is no doubt that recent advances have clarified that the incidence of CIN in relation to CT scanning (intravenous injection) is lower than previously thought (18) , but it is too early to declare that it is non-existing at least in patients with severely reduced renal function. Based on preclinical and cardiac studies, there is no doubt that contrast media are nephrotoxic. What are then the consequences of the recent advances? First of all, one should not deny a patient with a glomerular filtration rate between 30 and 45 mL/min 1.73m 2 a wellindicated enhanced CT scanning. It is probably too early to skip some hydration in those patients. Second, for patients with a GFR below 30 mL/min 1.73 m 2 , the occurrence of CIN cannot yet be ruled out. Very few patients with GFR 20 and 30 mL/min 1.73 m 2 have been enrolled and nearly no patients with GFR below 20 mL/min 1.73 m 2 have been enrolled in the various studies. They were generally excluded from many CIN studies. Therefore, we should still identify patients with GFR below 30 mL/min 1.73 m 2 and carefully evaluate whether the requested study should be performed under hydration or the patients should be MR-imaged or studied with an unenhanced CT scanning. If MRI and CT are equal for diagnostic point of view, one will still prefer to do enhanced MRI with a cyclic gadolinium-based contrast agent instead of CT with an iodine-based contrast medium (19) . Major prospective studies involving inpatients and outpatients who have a GFR between 45 and 30 mL/min 1.73 m 2 and who have GFR below 30 mL/min 1.73 m 2 are strongly warranted. They should include patients undergoing enhanced and unenhanced CT. Retrospective studies do not provide sufficient data to draw major conclusions. Whether the situation regarding CIN is similar for intra-arterial administration is still unknown and should be further examined. It is clear that all renal events are not due to the contrast medium as similar findings are in patients receiving no contrast medium. Also with regard to acute non-renal adverse events, the same events are seen after enhanced and unenhanced CT and MRI (20) . The recent advances have made it easier to be a radiologist, but it is too early to claim that CIN is not an adverse reaction to iodine-based contrast media when the patient undergoes CT. There is still a need for guidelines to reduce the risk of an acute kidney injury like those from ESUR (21) .
